[29 October 2017, Hong Kong] On October 28, Shanghai Fosun Pharmaceutical
(Group) Co.,Ltd. (referred to as “Fosun Pharma”) (stock code: 600196.SH,
02196.HK) announced that, its subsidiary, Shanghai Fosun Pharmaceutical
Industry Development Co., Ltd. received
a letter from the US Food and Drug Administration (referred to as "US
FDA") agreeing to clinical trials for the new drug FN-1501 used for
treatment of leukaemia.
The new drug FN-1501 is used for treatment of
leukaemia. Previously, Fosun Pharma’s R & D platform - Shanghai Shino-tech
Pharmaceutical Co., Ltd. had submitted to China Food and Drug Administration an
application for clinical trials of the new drug FN-1501 for leukaemia in China
(excluding Hong Kong, Macau and Taiwan), and the application was accepted in
At present, no drug has been offered in China that
possesses independent intellectual property rights and shares the same target
with the FN-1501; whereas a new drug sharing the same target was
offered in the US for the first time in 2017. As of September 2017, Fosun
Pharma at this stage has invested about RMB 23.5 million in research and
development of FN-1501.
Fosun Pharma always takes independent innovation as
the source power for enterprise development, and has been continuously
improving the drug R&D innovation system of "combining generic drugs
with innovative drugs". In recent years, the company continues to increase
R&D investment and has developed internationalized R&D structure and
strong R&D capabilities.